切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2018, Vol. 12 ›› Issue (03) : 129 -134. doi: 10.3877/cma.j.issn.1674-0807.2018.03.001

所属专题: 指南与规范 文献 指南共识

专家论坛

2018年美国《国家综合癌症网络乳腺癌临床实践指南》解读
李俊杰1, 邵志敏1,()   
  1. 1. 200032 上海,复旦大学附属肿瘤医院乳腺外科
  • 收稿日期:2018-04-12 出版日期:2018-06-01
  • 通信作者: 邵志敏

Interpretation of NCCN clinical practice guideline for breast cancer in 2018

Junjie Li1, Zhimin Shao1,()   

  1. 1. Department of Breast Surgery, Affiliated Tumor Hospital of Fudan University, Shanghai 200032, China
  • Received:2018-04-12 Published:2018-06-01
  • Corresponding author: Zhimin Shao
  • About author:
    Corresponding author: Shao Zhimin, Email:
引用本文:

李俊杰, 邵志敏. 2018年美国《国家综合癌症网络乳腺癌临床实践指南》解读[J/OL]. 中华乳腺病杂志(电子版), 2018, 12(03): 129-134.

Junjie Li, Zhimin Shao. Interpretation of NCCN clinical practice guideline for breast cancer in 2018[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2018, 12(03): 129-134.

美国国家综合癌症网络(NCCN)于2018年3月20日发布了2018年第1版《NCCN乳腺癌临床实践指南》。该指南结合乳腺癌领域最新的研究进展、新的循证医学证据和理念,在前期版本的基础上制定出当前乳腺癌诊治的指南与规范,供临床医师参考。笔者对最新版本中重要的变更内容进行解读,并结合中国的临床实际探讨其在中国推行的实用性和可行性,主要包括美国癌症联合会第8版乳腺癌TNM分期、保留乳房手术治疗和评估原则、前哨淋巴结活组织检查新进展和系统性治疗新策略4个方面。

The National Comprehensive Cancer Network (NCCN) launched the NCCN Clinical Practice Guideline for Breast Cancer (version 1) on March 20, 2018. This guideline reviews the latest research progress and treatment concepts in the field of breast cancer. On the basis of the previous versions, they update the guidelines for the diagnosis and treatment of breast cancer, which can assist physicians in their clinical practices. This paper interpreted the important changes in the latest version, and discussed its practicability and feasibility in China based on clinical practice, including the TNM staging of breast cancer by American Joint Committee on Cancer (AJCC) (the eighth edition), the principles of breast conserving surgery and pathological evaluation, the recent progress of sentinel lymph node biopsy and new strategy for systematic treatment.

[1]
National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: breast cancer. version 1.2018 [EB/OL].[2018-04-03].

URL    
[2]
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2017版)[J]. 中国癌症杂志,2017,27(9):695-759.
[3]
Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages Ⅰ and Ⅱ invasive breast cancer [J]. J Clin Oncol, 2014, 32(14): 1507-1515.
[4]
Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ [J].Ann Surg Oncol, 2016, 23(12): 3801-3810.
[5]
Galimberti V, Cole BF, Zurrida S, et al International Breast Cancer Study Group trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial[J]. Lancet Oncol, 2013, 14(4): 297-305.
[6]
Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial[J]. JAMA, 2017, 318(10): 918-926.
[7]
Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial[J].Lancet Oncol, 2014, 15(12): 1303-1310.
[8]
Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18[J]. J Clin Oncol, 1997, 15(7): 2483-2493.
[9]
Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J]. J Clin Oncol, 2003, 21(22): 4165-4174.
[10]
Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study[J]. Lancet Oncol, 2013, 14(7): 609-618.
[11]
Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: The SN FNAC study[J]. J Clin Oncol, 2015, 33(3): 258-264.
[12]
Boughey JC, Suman VJ, Mittendorf EA, et al. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance) [J]. Ann Surg, 2015, 261 (3): 547-552.
[13]
Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 [J]. J Clin Oncol, 2011, 29(25): 3366-3373.
[14]
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer [J].N Engl J Med, 2011, 365(14): 1273-1283.
[15]
von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer [J].N Engl J Med, 2017, 377(2): 122-131.
[16]
Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial [J].Lancet Oncol, 2017, 18(12): 1688-1700.
[17]
Tolaney SM, Barry WT, Dang CT et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer [J]. N Engl J Med, 2015, 372(2): 134-141.
[18]
Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer [J].N Engl J Med, 2016, 375(20): 1925-1936.
[19]
Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer [J].N Engl J Med, 2016, 375(18): 1738-1748.
[20]
Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer[J]. J Clin Oncol, 2017, 35(32): 3638-3646.
[21]
Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial [J]. Lancet, 2016, 388(10063): 2997-3005.
[1] 王亚红, 蔡胜, 葛志通, 杨筱, 李建初. 颅骨骨膜窦的超声表现一例[J/OL]. 中华医学超声杂志(电子版), 2024, 21(11): 1089-1091.
[2] 唐金侨, 叶宇佳, 王港, 赵彬, 马艳宁. 医学影像学检查方法在颞下颌关节紊乱病中临床应用研究进展[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(06): 406-411.
[3] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[5] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[6] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[7] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[8] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[9] 中国抗癌协会, 中国抗癌协会大肠癌专业委员会. 中国恶性肿瘤整合诊治指南-肛管癌(2024 版)[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 441-449.
[10] 李浩, 陈棋帅, 费发珠, 张宁伟, 李元东, 王硕晨, 任宾. 慢性肝病肝纤维化无创诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 863-867.
[11] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[12] 王子阳, 王宏宾, 刘晓旌. 血清标志物对甲胎蛋白阴性肝细胞癌诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 677-681.
[13] 陈慧, 邹祖鹏, 周田田, 张艺丹, 张海萍. 皮肤镜对头皮红斑性皮肤病辅助鉴别诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 692-698.
[14] 李茂军, 唐彬秩, 吴青, 阳倩, 梁小明, 邹福兰, 黄蓉, 陈昌辉. 新生儿呼吸窘迫综合征的管理:多国指南/共识及RDS-NExT workshop 共识陈述简介和评价[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 607-617.
[15] 胡云鹤, 周玉焯, 付瑞瑛, 于凡, 李爱东. CHS-DRG付费制度下GB1分组住院费用影响因素分析与管理策略探讨[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 568-574.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?